Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 20;7:13646. doi: 10.1038/s41598-017-13984-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

(a–g) Whole-body biodistribution analysis of ^99mTc-TROS and kinetics of TROS in serum and CSF of healthy and EAE mice. TROS was radio-labeled with ^99mTechnetium (^99mTc) and (a–d) 200 µg (72 MBq) ^99mTc-TROS was injected intraperitoneally (i.p.) in healthy wild type (WT) and hTNFR1 transgenic (Tg) mice. SPECT/CT acquisition was performed 1 h, 8 h and 24 h post-injection (n = 3/group/time point). (a–c) Biodistribution was assessed by measurement of activities in tissues based on the SPECT images at the different time points by AMIDE. (d) Representative coronal (C) and sagittal (S) views of fused SPECT/CT images of healthy WT (left) and hTNFR1 Tg (right) mice 24 h post-injection. (f,e) hTNFR1 Tg mice were immunized with MOG_35-55 and pertussis toxin to induce EAE and 16 days post-immunization (PI, peak of the disease) 500 µg (94.3 MBq) ^99mTc-TROS was injected i.p. in EAE and healthy hTNFR1 Tg mice (no EAE, n = 3/group). 8 h post-injection, SPECT/CT imaging was performed and representative coronal (C) and sagittal (S) pictures were taken of fused SPECT/CT images of healthy, no EAE mice (f, left) and EAE mice (f, right). (e) Biodistribution was assessed by measurement of activities in tissues based on the SPECT images 8 h post injection by AMIDE. (g) 500 µg TROS was injected i.p. in healthy (no EAE) and EAE hTNFR1 Tg mice 16 days PI. The concentration of TROS was determined in serum and cerebrospinal fluid (CSF) at the indicated time points. TROS levels were determined (n = 4‒7 serum/time point; n = 3‒4 CSF/time point). Data information: Bars (%ID/ml) and graphs represent mean ± SEM. Bio-distribution data were analyzed in all organs between the two groups with a two-way ANOVA and TROS kinetics in serum and CSF were compared at the indicated time points with an unpaired t-test. *0.01 ≤ p < 0.05; **0.001 ≤ p < 0.01; ***0.001 ≤ p 0.0001, ****p < 0.0001. Non-statistically significant differences are not indicated on the graphs.